Day 1, Friday November 24, 2017

07.30 REGISTRATION Formatted Table

BALL ROOM 1 BALL ROOM 3 A – EMERALD ROOM BALL ROOM 3 C – RUBY ROOM Formatted: Centered, Line spacing: 1.5 lines
08.00 A. MASTER CLASS for MC-IRSTC B, ROUND TABLE CROSS TALK (RTCT)-1 C. MEDICAL ONCOLOGY MASTER CLASS (MOMC)
– 1. Internship Doctors & General between Policy makers /Regulators, Producers 1. Internists, Internist Fellow Oncology (IFO), Trainees & Consultants Hematology -Medical Oncology (CHMO)

12.00 practitioners (GP) & Clinicians on SAFE BLOOD DONORS and 2. NEW INTERNIST FELLOW ONCOLOGY (New IFO) Program: a. Ministry of Health, RI, Fellowship Program;
b. REGULAR INTERNIST CERTIFICATE ONCOLOGY (ICO) & INTERNIST FELLOW ONCOLOGY (IFO) PROGRAM
2. Residents SAFE PLASMA DONORS
MOMC: “CANCER CELLULAR & MOLECULAR (CCM)” MASTER CLASS – PART 1
3. Specialists (Collaboration program between the Indonesian
Society of Hematology & Transfusion Medicine How to learn CELLULAR & MOLECULAR ASPECTS of CANCERS from TARGETED THERAPIES in
4. Trainees
(ISHTM/PHTDI) and the Indonesian Society of Blood SOLID TUMOR CANCERS and HEMATOLOGICAL CANCERS
5. Subspeciaists/Consultants (IRSTC)
Bank Doctors/ PDTDI)

08.00 MC-IRSTC, TUTORIAL 1, Session 1 RTCT-1 - SAFE BLOOD DONORS, Session 1 (08.00 – 09.00) MOMC , TUTORIAL 1, Session 1 and Session 2

THALASSEMIA MASTER CLASS (TMC) (Moderator: Current situation of NAT screening
BASIC MODULE test of TTI on blood donors in Indonesia)
Hemoglobinopathy: Thalassemias & Hb 1.1. How do we appropriately diagnose
variants/structural: Transfusion transmitted infections/TTI of
1.1.Basic principles, epidemmiology, hepatitis B or C & HIV (ELISA, NAT or RT-PCR ?)
molecular diagnosis & the use of family 1.2. If the blood donors are positive for TTI,
tree to diagnose thalassemia. what should we do with them? What is the role
CANCER CELLULAR & MOLECULAR (CCM) MASTER CLASS
1.1. Biosignaling pathways in normal cells: From ligands (signal molecules) to cell proliferation
1.2. How many are there the dysregulaton of signaling pathway developed in cancer cells ?
1.3. Why is it the dysregulation of biosignaling pathways in cancer cells occured ?
1.3. Dysregulation of the signaling pathways of extra cellular EGF superfamily pathways in solid tumor cancers
which are inhibited by monoclonal antibodies (MAb) of trastuzumab, pertuzumab, cetuximab, panitumumab
& VEGF pathway which is inhibited by MAb bevacizumab
1.4.Dysregulation of the signaling pathways of intracellular EGF (S) pathways in solid cancers which are
 1.2.Laboratory diagnosis (cytomor- of VCT? Could the TTI positive donors donate inhibited by smiall molecule inhibitors of gefitinib, erlotinib, afatinib, lapatib

phology, Hb electrophoresis) in beta & again their bloods after the TTI is negative?
alpha thalassemias. RTCT–1- SAFE BLOOD DONORS, Session 2
1.3. Discussion 2.1. The role of vaccination in negative blood
donors & anti-retrovirus (ARV) drugs in
prositive blood donors of hepatitis B or C
1.5. Dysregulation of the tyrosine kinases of ALK, ROS1, and MET which is ihbited by crizotinib
1.6. Dysregulation of multikinase pathways which are inhibited by sorafenib, sunitinib, regorafenib
1.7. Dysregulation of serine/threonine protein kinases which is inhibited by mTOR inhibitors (everolimus)
1.8. Dysregulatuon of proteomic pathway which is inhibited by bortezomib
2.1. How do we diagnose the dysregulation of those EGF, VEGF, ALK, multikinase and mTOR pathways?
2.2.How do we interprete the results of the tests?

08.50 MC-IRSTC TUTORIAL 1, Session 2 2.2. The role of ARV drugs in blood donors (09.00 – 09.40) MINISTRY of HEALTH, REPUBLIC INDOESIA PROGRAM on: “ The 2017 – the
TMC – BASIC MODULE with positif HIV. Ministry of Health (MOH), RI’s Support for “the Internist Fellow Oncology” (IFO Program
2.3. The safety of leucodepleted blood
2.1.Management of Thalassemia major. 1, The Ministry of Health(MOH), Republic Indonesia’s Regulation of the Support to “the Internist
2.2.Management of Thalassemia components compared to non filtered blood Fellow Oncology” (IFO) Program
Intermedia (TDT & NT) & Thalassemia components, 2, MOU between MOH RI and ISHMO (the Indonesian Society of Hematology – Medical Oncolog
PANEL DISCUSSION
minor. (ISHMO/ PERHOMPEDIN), the Indonesian Society of Internal Medicine (INASIM/PAPDI) - the
DRAFT of RECOMMENDATIONS from CLINICANS on
2.3. Duscussion Collegium of Internal Medicine (KIPD) on MOH,RI support to the IFO Program
“SAFE BLOOD DONORS for RECIPIENTS / PATIENTS”
3, The President of ISHMO speech
to MINISTRY of HEATLH, REPUBLIC INDONESIA
4, The President of INASIM speech
5, The Minister of Heath, RI, Representative speech
6, The Innaguration of the 2017 New IFO by Ministry of Health Representative

09.40 COFFEE BREAK and POSTER SESSIONS PRESS RELEASE,New IFO (VIP ROOM):PIC: Formatted: Centered, Line spacing: 1.5 lines
BALL ROOM 1 BALL ROOM 3 A – EMERALD ROOM BALL ROOM 3 C RUBY ROOM BALL ROOM 3 B – SHAPHIRE ROOM
Formatted: Centered, Line spacing: 1.5 lines
10.00 A. MASTER CLASS for Internship B. ROUND TABLE CROSS TALK (RTCT) - 1 C. MEDICAL ONCOLOGY MASTER CLASS (MOMC) ROUND TABLE CROSS TALK -3 (RTCT-3)

– Doctors, GP, Residents, between Policy makers /Regulators, Producers between Policy makers / regulators, Experts
CANCER CELLULAR & MOLECULAR MASTER CLASS
and Clinicians on PHARMACO-ECONOMY
12.00 Specialists, Trainees, Consultants (MC- & Clinicians on SAFE BLOOD DONORS and
(CCMMC) – PART 2 (Indonesian National CML ANALYSIS of ANTI HEMOPHILIC AGENTS
IRSTC) SAFE PLASMA DONORS
Working Group led by Prof Dr dr A Harryanto
Reksodiputro & the team)
10.00 MC-IRSTC, TUTORIAL 1, Session 3 and RCTC-1 Session 3 MOMC TUTORIAL 1, Session 3 and 4 (09.00 – 12.00) RTCT – 3

– Session 4 “SAFE PLASMA DONORS PRE- PLASMA 3.1. Normal abl-tyrosine kinase pathway A. Government regulation on INA-CBGs

12.00 TMC- BASIC MODULE
3.1. Iron overload/toxicity as a major
complication of Thalassemia major &
intermedia TDT & NTDT: From basic
science to clinical aspects (diagnosis &
treatment with iron chelating agents)
FRACTIONATION” 3.2 Why is it BCR translocated & integrated with abl? What package in the management of patients with
3.1.How do we select safe plasma donors in are the consquences ? hemophila A or B, which include:
Indonesia? 3.3. How is it the dysregulation of BCR-abl tyrosine kinase 1.1. Factor VIII and Factor IX concentrates
3.2. How do we select safe plasma donors in USA, pathway are inhibited by imatinib, nilotinib, ponatinib? 1.2. Complications of Hemophilia A and B:
Europe, based on the international standard/ 4.1. How do we diagnose BCR-abl translocation & interpret 1.2.1. Inhibitors of Factor VIII and IX
1.2.2. By-passing agents for patients with F
accreditation ? the results by cytomorpholgy and cytogenetics / karyotype?
3.3. How does the pharmaceutical company in 3.4. How do we diagnose BCR-abl translocation & interprete VIII inhibitors: Factor VII concentrate

3.2. Case study 1 & 2 : Europe selects plasma donors and processes the the results by BCR-abl qualitative test ? 2. Top up package for those above points

- How do we diagnose iron overload & plasma product appropriately based on the 3.5. When & how do we do BCR-abl qualitative test? B. Pharmaco-economy analysis from the

4. How do we provide the appropriate specimens for experts

organ iron toxicities ? international standard?
diagnosisng chronic myelogenous leukemia (CML) C. Plan of action:
- How do we give appropriate, PANEL DISCUSSION
4.1. Phlebotomy for peripheral blood diagnosis 1. Short term plans
DRAFT of RECOMMENDATION from CLINICIANS on
adequate and safe iron chelating
4.2. Bone marrow aspiration and bone marrow biopsy 2. Long term plans
“SAFE PLASMA DONORS pra PLASMA
agents 4. Complications of Thalassemia
4.3. Slide preparation of peripheral blood & bone marrow D. Draft of a RECOMMENDATION to the
FRACTIONATIONS for PATIENTS”to MINISTRY of
intermedia TDT versus NTDT. Government / Ministry of Health
HEALTH,Republic Indonesia 4.4. How do interprete the slides ?

12.00 FRIDAY PRAYING, LUNCH TIME and POSTER SESSIONS (BALL ROOM 2) Formatted Table
BALL ROOM 1 BALL ROOM 3A – EMERALD ROOM BALL ROOM 3 C – RUBY ROOM BALL ROOM 3 B – SAPHIRE ROOM
Formatted: Centered, Line spacing: 1.5 lines
13.00 MASTER CLASS for Internship ROUND TABLE CROSS TALKS (RTCT)-2, MEDICAL ONCOLOGY MASTER CLASS (MOMC) of RESIDENTS of the INTERNAL MEDICINE (RIM)

- Doctors, GP, Residents, Specialists, between Policy makers/ Regulators. Producers & “HTA MASTER CLASS of CANCER SYSTEMIC EXCLUSIVE MASTER CLASS (EMC)
(Department of INTERNAL MEDICINE ,
Formatted: Balloon Text, Line spacing: 1.5 lines, Tab
15.00 Trainees & Consulants (MC-IRSTC) Clinicians on Systemic Therapy in Cancers (Targeted THERAPY” (Cytotoxic chemotherapy, targeted
therapy of monoclonal antibodies (MAb), small UNIVERSITY INDONESIA, DR stops: 0.66", Left
CIPTO
therapy, hormonal therapy, biological therapy)
molecules & cytotoxic chemotherapies MANGUNKUSUMO HOSPITAL, JAKARTA)
1. Internists, Internist Fellow Oncology (IFO), Trainees &
(with keypads)
Consultants Hematology -Medical Oncology (CHMO) of
(+ New IFO)
Internal Medicine & Consultant Hematology-Oncology
 (CHO) of Pediatrics Formatted: Balloon Text, Line spacing: 1.5 lines, Tab
2.NEW INTERNIST FELLOW ONCOLOGY (New IFO) stops: 0.66", Left
13.00 IRSTC , TUTORIAL 1, Session 5 1.RTCT-2, Session 1 MOMC “HTA MASTER CLASS”, Session 1 RIM-EMC,TUTORIAL 1, Session 1
TMC BASIC MODULE 1.1.Overview of MAb:Comparison between originators MODULES of HTA and national&hospital guideline SUPPORTIVE THERAPY in CANCERS &
Chronic anemia as a major complication of &biosimilars,non-comparative biology/NCB in cancers PRACTICAL PROCEDURES’ MASTER CLASS
Moderator:
Thalassemas 1.2.Pivotal, originator & independent studies of 1.1, Cancer systemic therapy: Cytotoxic
1.1. How to develop Health Technology Assesment/HTA
Moderator. originators vs biosimilars of rituximab & trastuzumab chemotherapy. Targeted therapy, Hormonal
(with regards to efficacy & saftey) from critical appraisal
5.1. Chronic anemia as a major complication 2. RTCT-2, Session 2 therapy, Biological therapy: Classes &
(CA) of clinical studies/RCTs, systemic review/SR & meta-
of Thalassemia major: From basic science to 2.1. Overview of small molecule inhibitors: mechanism of actions
analysis/MA until grade of recommendation/GOR & cost
safe & appropiate blood transfusion. Comparison between originators & generics/copies 1.2, Adverse events and organ / system
effectiveness / CE analysis
5.2. Case studies: 2.2. Pivotal,originator & independent studies of small toxicities, and WHO grade of toxicities
1.2, How to develop National Guidelines or PNPK (Panduan
Approach of anemia or low MCV until molecule inhibitors of Imatinib & Bortezomib: criteria)
Nasional Pelayanan Kedokteran) & Hospital Guideline or PPK
thalassemia beta and alpha are diagnosed in originators vs generics/ copies (Panduan Praktek Kedokteran) from the HTA
various populations: 3.RTCT-2, Session 3 RIM-EMC TUTORIAL 1, Session 2
1.3. Discussion
a, Case study 1- In Thalassemia major. 3.1. Hospital Pharmacy Departement Policy on 2.1. When and how do we start with
b, Case study 2 - In Thalassemia intermedia originators,biosimilars,NCB&generics/copies of small PARENTERAL NUTRITION in CANCER
and Thalassemia minor. molecule inhibitor PATIENTS ?

3.2. Hospital Pharmacy Committee Policy on 2.2. When and how do we switch
14.00 MC-IRSTC TUTORIAL 1, Session 6 MOMC “HTA MASTER CLASS”, Session 2
originators, biosimlars.NCB & generics/copies of small PARENTERAL into ENTERAL NUTRITION in
TMC BASIC MODUL & CLINICAL HTA (efficacy & safety) of targeted of CETUXIMAB in the
molecule inhibitors CANCER PATIENTS?
TRANSFUSION MEDICINE HEAD & NECK (H&N) CANCERS
3.3. Producers perspective on biosimilars, NCB and 2.3. Case discussions
Moderator: Moderator:
generics / copies of small molecule inhibitors
2.1, When and why do we use leukodepleted 2.1. BPOM, FORNAS, FDA, EMA indication approvals
4.RTCT-2, Session 4 RIM-EMC, TUTORIAL 1, Session 3
blood components of PRCs in Thalassemia (presented by Moderator)
4.1. Draft of recommendations from clinicians on SUPPORTIVE THERAPY in CANCERS
patients? 2.2. Profile of Cetuximab in H & N cancers and pivotal,
biosimilars & generics/copies of targeted therapies of 3.1 How do we prevent and treat FEBRILE
2.2, When and why do we choose TC originator, independent studies of Cetuximab in H&N
MAbs and small molecule inhibitors NEUTROPENIA post cytotoxic
apheresis and do therapeutic apheresis? cancer.
4.2. National Committe Expert of BPOM & FORNAS’ chemotherapy?
2.3. Critical appraisal,grade of recommendation & algorithm
 perspective on MAb biosimilar,NCB & generics/copies of CETUXIMAB in H&N Cancer When do start with G-CSF ?
small molecule inhibitors 2.4. Discussion & Conclusion (presented by Moderator)

15.00 MC-IRSTC TUTORIAL 2 4.3. BPOM (the Indonesian FDA) policies/regulations MOMC “HTA MASTER CLASS”, Session 3 RIM-EMC , TUTORIAL 1, Session 4

MC MmRSTC TUTORIAL 2, Session
on biosimilars,NCB&generics/ copies of small HTA of targeted therapy of CETUXIMAB in COLORECTAL 4.1, How do we prevent and treat NAUSEA,
molecule inhibitors CANCER: Moderator: VOMITING and STOMATITIS ?
4.4. Ministry of Health,RI’ policies/regulations on 3.1. BPOM, FORNAS, FDA, EMA indication approvals
biosimilars, NCB nd generics/copies of small molecule (presented by Moderator) RIM-EMC, TUTORIAL 2, Session 1
inhibitors Director General of Pharmacy & Medical 3.2. Profile of Cetuximab in MCRC and Pivotal, originator, “Pre -, durante – post- chemotherapy
Equipment, MOH,RI independent studies of Cetuximab in MCRC. assessment” in cancer patients
5. RTCT-2 Session 5: 3.3, Critical appraisal, grade of recommendation&algorithm 1,1. Why do we have to assess performance
5.1. PANEL DISCUSSION (All speakers & Moderators) of CETUXIMAB in METASTATIC COLORECTAL CANCERS. status (PS) & body surface area (BSA) every
5.2.RECOMMENDATIONS from CLINICIANS to pre-chemotherapy ? How to do theses?
POLICY MAKERS /REGULATORS and PRODUCERS on 3.4. Discussion & Conclusion (by Moderator) 1,2.Why, when & how do we assess ORGAN

16.00 MC-IRSCT TUTORIAL 3 BIOSIMILARS, NCBand GENERICS/COPIES of small MOMC “HTA MASTER CLASS”, Session 4 TOXICITIES WHO SCORE of cytotoxic

– molecule inhibitors in Cancers SEVERAL INVASIVE PROCEDURES /TREATMENTS in chemotherapies ?

HEMATOLOGY-ONCOLOGY: to be developed into 1.3. When and how do we assess treatment

17.30
MULTIDICIPLINARY CONSENSUS responses ? Using WHO Score or RECIST

4.1. CHEMORADIATION SCORE?

2, INTRATHECAL CYTOTOCIX CHEMOTHERAPY in

PATIENTS with THROMBOCYTOPENIA
3. DENTAL PROCEDURES in PATIENTS with RIM-EMC TUTORIAL 2, Session 2

THROMBOCYTOPENIA or HYPOCOAGULATION HEMATOLOGY - ONCOLOGY DAILY

ANTI THOMBOTIC THERAPY MASTER CLASS PRACTICES MASTER CLASS

Moderator: 2.1. Invasive procedures in Hematology-

3.1. Hemostasis & Pathogenesis of thrombosis Oncology:

3.2. Riak and trigger factors of thrombosis Bone marrow aspiration & biopsy, fine

3.3. Classes of anti thrombotic agents: Anti coagulants needle & core biopsies

(conventional & New Anti-coagulants / NOAC, anti platelet,

 thrombolytic agents and their mechanism of actions, 2.2. Leukodepleted blood components (PRC
3,4, When & how do we administer anti-coagulants/NOAC and TC) using bed side & blood bank filters
? and apheresis machine (thrombapheresis)
3.5. Bleeding is a major complication of anticoagulants. How 2.3. Plasmapheresis in auto immune diseases
do we cope this? (Gullian Baree. Myasthenia gravis, others)

3.6. What should we do if the patients on anticoagulants

(NOAC) will undergo surgery or teeth extraction? Shoud do
we do bridging therapy?
3.7. Case studies MC-IRSTC TUTOR

17.00 COFFEE BREAK and POSTER SESSIONS Formatted Table

17.20 END OF THE DAY ! SESSIONS of SCIENTIC MEETINGS a

19.00 BALL ROOM 3 B - SAPHIRE ROOM and 3 C RUBY ROOM (merged, round table)

19.00 DINNER SYMPOSIUM – 1

HTA of GOSERELIN ACETATE (leutinizing hormone releasing hormone/LHRH agonist) in BREAST CANCER &

GEFITINIB in METASTATIC LUNG CANCER (NCSLC)

1. BPOM, FORNAS, FDA, EMA indication approvals of Goserelin Acetate & Gefitinib (by Moderator)
2. The role of Goserelin Acetate/LHRH in Breast Cancer and the pivotal studies to support its indications
3, The role of Gefitinib metastatic in non small cell lung cancer (NSCLC)

20.00 1, Organizaton Meeting A (PERHOMEDIN)

PERHOMPEDIN DEVELOPMENT PROGRAM of Internist CERTFICATE ONCOLOGY (ICO), Internist
FELLOW ONCOLOGY (IFO) and CONSULTANT HEMATOLOGY-MEDICAL ONCOLOGY (CHMO)
throughout INDONESIA
1.1. ICO and IFO Program:REGULAR NATIONAL program&MINISTRY of HEALTH-STUDY
SUPPORT program
 1.2. The Inaguration of IFO who have already got the Certicate from Kolegium Ilmu Penyakit
Dalam (KIPD) and from PERHOPEDIN
1.3. Welcome to the new ICO and IFO Programs
1.4. Consultant -Hematology-Medical Oncology (KHOM) Program : How to join this program in 15
Centers of KHOM in Indonesia
2. Organization Meeting B (PHTDI & PERHOMPEDIN & PTHI)
2. 1. COLLABORATIVE EDUCATION PROGRAM of PHTDI & PERHOMPEDIN in 10 provinces throughout
Indonesia 2017-2019 on HOTT (Hemophilia,Oncology Supportive Therapy,Thalassemia & Transfusion)
2.2. Highlight of American Society of Hematology in Asia Pacific (HOA-APAC) (Bali Nusa Dua Convetion
Cetre) March 08-10, 2018, Bali, Indonesia

21.30 END of DAY 1 All Sessions

Day 2, Saturday, November 25, 2017
07.30 REGISTRATIONMOde

BALL ROOM 1 BALL ROOM 2 MEETING ROOM 2 and MEETING ROOM 3 (merged)

08.00 – MEDICAL ONCOLOGY MASTER CLASS (MOMC) for: 1.Exhiebitions: RESIDENTS of the INTERNAL MEDICINE (RIM) EXCLUSIVE MASTER CLASS
Formatted: Font: (Default) Segoe UI Light, 11 pt
12.00 1. Internists, Internist Fellow Oncology (IFO), Trainees & Consultants of (EMC)
a.Hematology Scientific Quiz
Hematology -Medical Oncology (HMO) & Hematology-Oncology (HO) pf (Department of INTERNAL MEDICINE , UNIVERSITY INDONESIA, DR CIPTO
Pediatrics for Internship Program
MANGUNKUSUMO HOSPITAL, JAKARTA) (With key pads)
2.NEW INTERNIST FELLOWSHIP ONCOLOGY (NIFSO) PROGRAM Doctors
Integrated CLASS for Internship Doctors & GP, Residents,
b. Oncology Scientific Quiz
Specialists, Trainees, Consultants (MC-IRSTC)
for Internship Program
08.00 MOMC “HTA MASTER CLASS”, Session 5 RIM-EMC TUTORIAL 3,Session 1&2, ADULT THALASSEMIA MASTER CLASS-PART 1
HTA of CRIZOTINIB in METASTATIC ALK posotive LUNG CANCERS Doctors Iron overload/toxicity as a major complication of Thalassemia majorFormatted:
& Font: (Default) Segoe UI Light, 11 pt
Modeator:
2.Poster sessions: Slide intermedia (Transfusion dependent thalassema/TDT & Nnon TDT/NTDT). Formatted: Font: (Default) Segoe UI Light, 11 pt
2.1. BPOM, FORNAS, FDA, EMA approvad indications of Crizotinib
(presented by Moderator) poster presentations 1.1, What is iron overload?Why and how does iron overload occur? How do we
measure iron overload?
2.3.Critical Appraisal,Grade of recommendation and Algorithm of (Selected posters)
1.2,What is organ iron toxicities?Why and how do various iron toxicities occur ?
CRIZOTINIB in ALK positive LUNG CANCERS
1. Formatted: Font: (Default) Segoe UI Light, 9 pt, Bold
How do we diagnose iron toxicities in various organs ?
08.50 MOMC “HTA MASTER CLASS”, Session 6 Formatted: Line spacing: 1.5 lines, No bullets or
1.3, When do we start with iron chelator agents? How do we choose and
HTA of ABIRATERON in METASTATIC PROSTAT CANCER (MPC) numbering, Tab stops: 0.66", Left + Not at 0.5"
adminter those iron chelating agents?
Moderator:
2.1. BPOM, FORNAS, FDA, EMA approved indications of Abirateron
(presented by Moderator) RIM-EMC, TUTORIAL 3, Session 2, ADULT THALASSEMIA MASTER CLAS-PART 2

2.2. Profile of ABIRATERON and pivotal, originator, independent studies 2.1.Case study 1 - How do we diagnose iron overload & organ iron toxicities ?
2.3.Critical Appraisal,Grade of recommendation and Algorithm of Case study 2 - How do we give appropriate, adequate & safe iron
ABIRATERON in Metastatic Prostat Cancer (MPC) chelating
 agents
2.2. What are the other complications of Thalassemias beside iron overload /
iron toxicity?

09.40 COFFEE BREAK and POSTER SESSIONS (BALL ROOM 2) Formatted Table
BALL ROOM 1 BALL ROOM 2 MEETING ROOM 2 and MEETING ROOM 3 (merged)

MEDICAL ONCOLOGY MASTER CLASS (MOMC) for: RESIDENTS of the INTERNAL MEDICINE (RIM) EXCLUSIVE MASTER CLASS
1. Internists, Internist Fellow Oncology (IFO), Trainees & Consultants of (EMC)
Hematology -Medical Oncology (HMO) & Hematology-Oncology (HO) pf (Department of INTERNAL MEDICINE , UNIVERSITY INDONESIA, DR CIPTO
Pediatrics
MANGUNKUSUMO HOSPITAL, JAKARTA) (with keypads)
2. NEW INTERNIST FELLOWSHIP ONCOLOGY (NIFSO) PROGRAM

Integrated CLASS for Internship Doctors, GP, Residents, Specialists,

Trainees, Consultants (MC-IRSTC)

Formatted Table
10.00 MOMC “HTA MASTER CLASS”, Session 7 1.Exhiebitions: RIM-EMC TUTORIAL 4, Session 1 and Session 2
HTA of targeted therapy of AFATINIB in LUNG CANCERS (NSCLC) a.Hematology Scientific Quiz for BLEEDINGS MASTER CLASS: From basic science to clinical applications
2.1. BPOM, FORNAS, FDA, EMA approved indications of AFATINIB
Internship Program Doctors 1,1. Basic principle of primary, secondary and tertiary hemostasis & control
(presented by Moderato
b. Oncology Scientific Quiz for mechanisms
2.2. Profile of AFATINIB: Class of drug, mechanism of action& how we use
Internship Program Doctors 1.2. Diseases or abormalities of primary, secondary and tertiary hemostasis
it?
2.Poster sessions: Slide poster 1.3. Bleeding due to platelet abnormalities: Quantitative ? or Qualitative ?
2.2. Pivotal (LUX LUNG 3,6,7), originator, independent (systematic review)
studies, presentations (Selected posters)

2.3.Critical Appraisal,Grade of recommendatin of AFATINIB in NSCLC 2.1, How do we approach of thrombocytopenia until isoted trombocytopenia
(ITP) is diagnosed? Are there any laboratory tests to confirm itp diagnosis?

11.00 MOMC “HTA Master Class”, Session 8 When do we undergo bone marrow aspiration in ITP?
Filgatrim & Pegfilgrastim in Bone Marrow Transplantation & HTA of 2.2.What are the current ITP treatment? How do they work? When do we use
FLUDARABINE in LYMPHOID CANCERS
 2.1. Profile of G-CSF Filgrastim & Peg-filgastrim, and their roles in BMT IvIg ?
2.2. BPOM, FORNAS, FDA, EMA approved indications of FLUDARABINE 2.3.When do we use eltrombophage? How does it work?
(presented by Moderator)
2.4. When and why do we give platelet transfusion in ITP?
2.3. Profile of FLUDARABINE and its pivotal, originator, independent studies.
2.5. When and why do we perform splenectomy?
Critical appraisal , grade of recomendation & algorithem of fludarabine
2.6. Case discussion

12.00 LUNCH TIME and POSTER SESSIONS

BALL ROOM 1 BALL ROOM 2 MEETING ROOM 2 and MEETING ROOM 3 (merged)

Formatted Table

13.00 – MEDICAL ONCOLOGY MASTER CLASS (MOMC) for: 1.Exhiebitions: RESIDENTS of the INTERNAL MEDICINE (RIM) EXCLUSIVE MASTE CLASS (EMC)
17.00 1, Internists, Internist Fellow Oncology (IFO), Trainees & Consultants of a.Hematology Scientific Quiz for (Department of INTERNAL MEDICINE , UNIVERSITY INDONESIA, DR CIPTO
Hematology -Medical Oncology (HMO) & Hematology-Oncology (HO) pf Internship Program Doctors MANGUNKUSUMO HOSPITAL, JAKARTA (with keypads)
Pediatrics
b. Oncology Scientific Quiz for
2, NEW INTERNIST FELLOWSHIP ONCOLOGY (NIFSO) PROGRAM
Internship Program Doctors
2.Poster sessions: Slide poster
Integrated CLASS for Internship Doctors, GP, Residents, Specialists,
presentations (Selected posters)
Trainees, Consultants (MC-IRSTC)

13.00 MOMC “HTA Master Class”, Session 9 RIM-EMC TUTORIAL 5 Session 1 and 2
HTA of targeted therapy of BORTEZOMIB in MULTIPLE MYEOMA (MM) ANTI THROMBOTIC THERAPY MASTER CLASS
2.1. BPOM, FORNAS, FDA, EMA approved indications of BORTEZOMIB
1.1. How is thrombus developed? (Pathogenesis of thrombosis)
(presented by Moderator)
1.2. What are the risk and trigger factors of thrombosis, either venous
2.2. Profile of BORTEZOMIB, Pivotal, originator, independent studies
thrombosis or arterial thrombosis ?
1.3. How do we define hypercoagulable state? How do we define
2.3. Critical appraisal, grade of recommendation of BORTEZOMIB in MM
hypercoagulation ? Are there any differencec with regards to phases of
14.00 MASTER CLASS of Hodgkin lymphoma (TAKEDA), Session 9 - Part 1
Optimizing Prompt Diagnosis of Hodgkin Lymphoma
9.1 Essential Diagnosis and Biomarkers for Hodgkin Lymphoma
9.2 Role of Imaging Assestment in Hodgkin Lymphoma
9.3 Discussion
15.00 MASTER CLASS of HL, Session 9 -Part 2
Unmet Need in the Management of Advanced-Stage Hodgkin
Lymphoma
9.4 Current treatment Landscape: A Focus on ABVD and BEACOPP
9.5 Future Landscape of HL Treatment: Where Do We Go From
Here?
9.6 Discussion-16.00
16.00 MASTER CLASS of HL, Session 9 – Part 3
Long Term Complications of the Hodgkin Lymphoma Treatment
9.7 Managing the Cardiovascular and Second Malignancy in the
Breast
thrombosis and coagulation tests?
1.4. Classes of anti thrombotic agents: Anti coagulants (conventional & New
Anti-coagulants / NOAC, anti platelets , thrombolytic agents and their
mechanism of actions.
1.5, When and how do we give those anti-coagulant agents ?
2.1, When do we monitor the efficacy & safety of those anticoagulants? What
are the laboratory tests we should choose?
2.2. How should we do if the patient is on anti-coagulant agents will undergo
surgery or teeth extraction? Shoud we do bridging therapy?
2.3. Case discussions
Formatted Table
RIM-EMC, TUTORIAL 6, Session 1 and Session
CANCER PAIN MANAGEMENT MASTER CLAS (BASIC and INTERMEDIA MODULES)
1. Pathegenesis of cancer pain
2. How do we assess the cancer pain and how do we use the score system ?
3. When do we start with cancer pain killer and what kind of pain killer shoud
we choose?
4. When do we start with opioid in cancer pain ? What kind of opioid should we
Formatted: Font: (Default) Segoe UI Light, English
choose? Is it safe for patients? (United States)
5. How do we switch the opioids from one drug to another?
6, Are there any other measures in cancer pain management ?
7, Case discussion
 9.8 How to Preserve Fertility in HL
9.9 Discussion

17.00 COFEE BREAK AND POSTER SESSIONS SPECIAL GROUP MEETING:

Post marketing surveillance of ERIBULIN in Metastatic Breast Cancer (MBC)

19.00 DINNER SYMPOSIUM 2 Formatted: Left, Line spacing: 1.5 lines

“BRENTUXIMAB VEDOTIN in HODGKIN LYMPHOMA” LAUNCHING
PROGRAM
Moderator:
19.10- HOLYSA Study Result
19.25

19.25- Indonesia experience on HL management

19.40

19.40- Novel targeted therapy on R/R HL and sALCL

20.00

20.00- Q &A
20.15

20.15- Adcteris launching Journey

20.30

20.30- Dinner
21.00
21.00 Indonesian National Venous Thromboembolism (VTE) Working
Group Meeting of INASTH:
- National Multicenter Study on LMWH in DVT (IDENTIA
Study)Sanofi
- National Guideline on the Use of Anticoagulants

22.30 END of DAY 2 All Sessions

 Day 3, Sunday, November 26, 2017
07.30 REGISTRATION Formatted Table
BALL ROOM 1 BALL ROOM 3 B-SAPHIRE ROOM + 3 C RUBY ROOM (merged) BALL ROOM 3 A – EMERALD ROOM Formatted: Centered, Line spacing: 1.5 lines
08.00 MASTER CLASS for Internship Doctors, MEDICAL ONCOLOGY MASTER CLASS (MOMC) RESIDENTS of the INTERNAL MEDICINE (RIM) EXCLUSIVE
– Residents, Specialists, Trainees, Consultants (MC- 1. Internists, Internist Fellow Oncology (IFO), Trainees & Consultants of Hematology - MASTER CLASS (EMC)
12.00 IRSTC) Medical Oncology (HMO) & Hematology-Oncology (HO) pf Pediatrics (Department of INTERNAL MEDICINE , UNIVERSITY
2.NEW INTERNIST FELLOWSHIP ONCOLOGY (NIFSO) PROGRAM
INDONESIA, DR CIPTO MANGUNKUSUMO HOSPITAL,
JAKARTA) (with keypads)

08.00 MC-IRSTC, TUTORIAL 4, Session1 and Session 2 MOMC on BIOPSY and THERAPEUTIC APHERESIS SPECIAL CLASS RIM-EMC TUTORIAL 7, Session 1

– “BLEEDINGS MASTER CLASS” (BMC) – PART 2: THROMBOSIS MASTER CLASS – PART 1: DVT and PE

09.40 BMC Seesion 1: From basics to clinical aspects 1.Bone marrow aspiration, bone marrow biopsy, lymph node fine needle
1, How do we predict deep vein thrombosis (DVT) in patients with
1,1. Basic principle of primary, secondary and aspiration, lymph node core biopsy
no signs of DVT?
tertiary hemostasis & required laboratory tests 1.1.When do we do those procedures ? (Indications)
2, When and how do we use of the risk scoring system of DVT in
1.2, Bleeding due to diseases or abormalities of 1.2.What should we do before, during & after ?
patients with hypercoagulable state and no sign of DVT ?
primary, secondary and tertiary hemostasis 1.3.What sholud we do with the specimens ?
3, How do we prevent DVT with primary anticoagulant prophilaxis?
BMC,Session 2: Bleeding due to platelet 1.4.How do we interprete the results ? 4, How do we diagnose patients with suspected DVT with Wells

abnormalities score?

2.1, How do we approach thrombocytopenia until 2Therapeutic plasma exchange (TPE) / Plasmaphersis as the first choice in 5. Which algorithm is used to confirm DVT diagnosis?

immunological diseases (e.g. Gullian Baree, Myasthenia gravis and others) 6.How do we treat acute DVT ?
isotlated trombocytopenia (ITP) is diagnosed?
7. Discussion
2.2.Are there any laboratory tests to confirm
RIM-EMC TUTORIAL 7, Session 2
MOMC “HTA MASTER CLASS”, Session 11
diagnosis? When do we do bone marrow
1, Pulmonary embolism (PE) is an acute complication of DVT. When
CLINICAL OVEVIEW of ERIBULIN in METASTATIC BREAST CANCER (MBC)
aspiration?
do we suspect that our patients are PE ?
2.3.What are the current ITP treatment? When do 2, When and how do we use GENEVA Score System for Suspected
1, BPOM, FORNAS, FDA, EMA approved indications of Eribulin (presented by
we use Intravenous Immunoglobulin (IvIg) PE?
Moderator)
 2.4. When do we use eltrombophage? 2. Profile of ERIBULIN and pivotal, originator, independent studies 3, Which algorithm is used to confirm PE diagnosis ?

2.5. When are platelet transfusion and 3. Critical Appraisal (CA), Grade of Recommendation (GR) and Algorithm of ERIBULIN 4, How do we treat PE
in MBC. 5, Discussion ? Formatted: Font: (Default) Segoe UI Light, 8 pt
splenectomy indicated?
3. Case studies

09.40 COFFEE BREAK and POSTER SESSIONS (BALL ROOM 2) Formatted Table
BALL ROOM 1 BALL ROOM 3 A – EMERALD ROOM & BALL ROOM 3 B – SHAPHIRE ROOM BALL ROOM 3 C – RUBBY ROOM
(merged)

MASTER CLASS for Internship Doctors, MEDICAL ONCOLOGY MASTER CLASS (MOMC) RESIDENTS of the INTERNAL MEDICINE (RIM) EXCLUSIVE
Residents, Specialists, Trainees, Consultants 1. Internists, Internist Fellow Oncology (IFO), Trainees & Consultants of Hematology - MASTER CLASS (EMC) (Department of INTERNAL MEDICINE
(MC-IRSTC) Medical Oncology (HMO) & Hematology-Oncology (HO) pf Pediatrics , UNIVERSITY INDONESIA, DR CIPTO MANGUNKUSUMO
2.NEW INTERNIST FELLOWSHIP ONCOLOGY (NIFSO) PROGRAM
HOSPITAL, JAKARTA) (with keypads)

10.00 MC-IRSTC TUTORIAL 5, Session 1 and Sesson 2 MOMC “HTA MASTER CLASS”, Session 12 RIM-EMC TUTORIAL 8, Session 1,

SUPPORTIVE THERAPY in CANCERS, Session 1: HTA of PEMBROLIZUMAB (the only one innunotherapy approved in cancer systemic THROMBOSIS MASTER CLASS - PART 2: ARTERIAL THROMBOSIS

1.1, Cancer systemic therapy: Cytotoxic chemotherapy. therapy) in LUNG CANCER (NSCLC) 1.1, How doed the srterial thrombosis develop? (Pathogenesis)

Targeted therapy, Hormaonal therapy, Biologicl 1, BPOM, FORNAS, FDA, EMA approvals 1.2, Are there any risk and trigger factors for arterial thrombos?

therapy: Classes & mechanism of actions 2, Basic immunology of Immunotherapy in Cancers 2.1. How do we predict and diagose arterial thrombosis such as

1.2, Adverse events and organ / system toxicities, and 2. Profile, mechanism of actiom, pivotal, originator, independent studies of peripheral arterial diseases (PAD) and mesenterical thrombosis ?

WHO garde of toxicities criteria) PEMBROLIZUMAB 2.1, Can we treat and prevent arterial thrombosis with anti platelet

1.3, How do we prevent and treat nausea, vomiting & 3. Critical appraisal, Grade of recommendations, and algorithm of PEMBROLiZUMAB agents ?

stomatitis? in LUNG CANCERS (NSCLC) 3.1. Are there any laboratory tests can help diagnosis aretrial

SUPPORTIVE THERAPY in CANCERS, Session 2: thrombosis?

2.1. When do we start with parenteral nutrition for 3.2, What are the role of platelet aggregation test and platelet

cancer patients ? function assay (PFA) in monitoring the efficacy and safety of anti
platelet agents?
2.2. When do we switch parenteral into enteral nutition
in cancer patients?
3. Case discussions
11.00 Join Ballroom 3 B SHAPHIRE & 3 C RUBY for
LUNCH SYMPOSIUM
12.00
BALL ROOM 1
MASTER CLASS for Internship Doctors,
Residents, Specialists, Trainees, Consultants
13.00 MC- IRSCT TUTORIAL 6, Session 1 and Session 2
– CANCER PAIN MANAGEMENT MASTER CLASS, BASIC
MODULE
15.00
1. 1. Pathegenesis of cancer pain
1. 2. How do we assess the cancer pain and how
do we use the scoring system ?
2.1. When do we start with cancer pain killer and what
kind of pain killer shoud we chhose?
2.2. When do we start with opoid cancer pain ? Which
LUNCH SYMPOSIUM: CLINICAL APPLICATIONS of PERTUZUMAB plus JOIN BALL ROOM 3 B SAPHIRE and 3 C RUBY for LUNCH
TRASTUZUMAB and DOCETAXEL in Metastatic Breast Cancers (MBC) SYMPOSIUM
“PERTUZUMAB, HER2 Dimerization Inhibitor (HDI), a new targeted therapy
in Breast Cancer”
Moderator: tbc
1.Profile of PERTUZUMAB and CLEOPATRA, a Pivotal Phase III Study of
PERTUZUMAB (combined with Trastuzumab and Docetaxel in MBC)
2. Case studies
LUNCH and POSTER SESSIONS (BALL ROOM 2) Formatted Table
BALL ROOM 3 A – EMERALD ROOM & BALL ROOM 3 B – SHAPHIRE ROOM BALL ROOM 3 C – RUBBY ROOM
(merged)
MEDICAL ONCOLOGY MASTER CLASS (MOMC) RESIDENTS of the INTERNAL MEDICINE (RIM) EXCLUSIVE MASTER
1. Internists, Internist Fellow Oncology (IFO), Trainees & Consultants of Hematology - CLASS (EMC) (Department of INTERNAL MEDICINE , UNIVERSITY
Medical Oncology (HMO) & Hematology-Oncology (HO) pf Pediatrics INDONESIA, DR CIPTO MANGUNKUSUMO HOSPITAL, JAKARTA)
2.NEW INTERNIST FELLOWSHIP ONCOLOGY (NIFSO) PROGRAM (with keypads)
MOMC “HTA MASTER CLASS”, Session 13 RIM-EMC TUTORIAL 8 – Session 2
Part 1: HTA of TRASTUZUMAB in METASTATIC BREAST CANCER (MBC) ARTERIAL THROMBOSIS MASTER CLASS – PART 2
1.1. BPOM, FORNAS, FDA, EMA approvaled indications of TRASTUZUMAB in MBC (by
1,How do we diagnose and treat arterial thrombosis of retinal
Moderator)
arterial and venous thrombo-emboli?
1.2. Pivotal, originator, independent studies of TRASTUZUMAB in MBC
2,How do we diagnose and treat sudden deafness due to
1.3. Critical appraisal, Grade of recommendation and Algorithm of TRASTUZUMAB in
arterial thromboemboli?
MBC ,
Part 2: Pharmaco-economy assesesment of TRASTUZUMAB in MBC 3,How do we diagnose and treat mesenterical trhombo
2.1.Cost effectiveness / Cost utility / QALY assesment of TRASTUZUMAB in MBC: to be emboli?
confirmed
 one?Is it safe for patiensts?
2.3. Case studies
TUTORIAL Session 2
3.1. When do we start with cancer pain killer and what
kind of pain killer shoud we choose?
3.2. When do we start with opoid cancer pain ? Which
one? Is it safe for patients?
3.3. Case studies
15.00 MC-IRSCT TUTORIAL 7
VENOUS THROMBOEMBOLI MASTER CLASS – PART 1
1, When and how do we use the risk scoring system of
DVT in patients with hypercoagulable state and no sign
of DVT?
2, How do we diagnose patients with suspected DVT
with Wells score, followed by ACCP/Colman algorithm?
3.How do we treat acute DVT ?
4, How do we prevent DVT with primary anticoagulant
prophilaxis?
7. Discussion
VENOUS THROMBOEMBOLI MASTER CLASS – PART 2
1.Pulmonary embolism (PE) is an acute complication of
DVT. When do we suspect that our patients are PE ?
2.2. National Health Insurance Report: National expences of cancer systemic therapy
(including Targeted therapy). 2.3. Ministry of Health, Republic Indonesia, regulation in
cancer systemic therapy (including targeted therapy):
3. PANEL DISCUSSION to DEVELOP RECOMMENDATION
RIM-EMC TUTORIAL 9
BLEEDING MASTER CLASS
9.1. HEREDITARY BLEEDING (Hemophilia, von Willebrand)
9.2. ACQUIRED BLEEDING due to:
a. DIC, TTP, AA, and MDS
b, Anti thrombotic agents: Warfarin, NOACs, UFH, LMWH, anti
platelet and thrombolytic agents
MOMC “HTA MASTER CLASS” , Session 14 RIM-EMC TUTORIAL 3, Session 3
HTA, PNPK, PPK, Cinical Pathway – PAR - 1 ADULT THALASSEMIA MASTER CLASS – PART-3
1.How to develop CLINICAL PATHWAYS (CP) in CANCER SYSTEMIC THERAPIES from
Case dicussions
HTA, PNPK, PPK
2.Chronic anemia in Adult Thallasemia major & intermedia
2. SELF PRACTICING to develop HTA, PNPK, PPK & CP of systemic therapies in
(TDT & NTDT)
cancers
3.Safe and optimal blood transfusion
4.Complications of chronic anemia: How to diagnose, to
treat and to prevent
Case dIscussions
5, How to diagnose thalassemia α and β, and Hb-pathies in
adult patients
6, How to define TDT & NTDT
7.How to do Thalassemia prevention?
 2, When and how do we use GENEVA Score System for
Suspected PE, followed wih ACCP Algorithm
3, How do we trea PE ????,
3, Discussion ?

16.00 MC-IRSCT TUTORIAL 8
BLEEDING MASTER CLASS (BMC)
7.1. Acquired bleeding: DIC, TTP, AA, MDS
7.2. Aquired bleeding due to anti thrombotic agents:
anti-coagulants, anti platelet and trombolytic agents
MOMC “HTA MASTER CLASS” , Session 14 RIM-EMC TUTORIAL 10
HTA, PNPK, PPK, Cinical Pathway – PAR - 1 IRON DEFICIECY ANEMIA MASTER CLASS
1.How to develop CLINICAL PATHWAYS (CP) in CANCER SYSTEMIC THERAPIES from 1, How do we choose IRON PREPARATIONS?
HTA, PNPK, PPK 2, Why are we recommended to choose ferri- prepaaarations rather
2. SELF PRACTICING to develop HTA, PNPK, PPK & CP of systemic therapies in than Ferro preparations?
cancers 2. When do we choose oral iron preparations and iron injections
?

17.00 COFFEE BREAK and POSTER SESSIONS a Formatted Table

17.20 END of the 2017 ISMI HOTTI
WEDNESDAY, November 22rd, 2017
REGISTRATION Formatted: Centered, Line spacing: 1.5 lines

07.30

AUDITORIUM , level 1, FKUI Speakers Notes Formatted: Centered, Line spacing: 1.5 lines
08.00 A. MASTER CLASS for MC-IGP
– 1. Internship Doctors : Pre program
12.00 2. Internship Doctors; Post program
3. General practitioners (GP) in the Primary Health Service
(IGP)

BLOOD TRANSFUSION MASTER CLASS

(BTMC): “Safe and appropriate use of blood trasfusion in clinics”

08.00 IGP – BTMC, TUTORIAL 1.

Welcome speech form the Dean of Medical Faculty, University Indonesia

08.15– Session 1.
08.45 “Phylosophy of blood transfusion: Safe and appropriate use of blood”
 1.1, WHO (1997 – 1998) 7 key points of the Appropriate use of blood”
1.2. Flow chart of the Safe and appropriate use of blood
1.3. When is blood transfusion indicated? When is blood transfusion contraindicated?
08.45 1.4. When do we need blood transfusion for our patients? What kind of donor bloo required?
– Discussion
09.00

09.00- Session 2.
09.30 “Blood banking”- Safe donor blood - Part 1
2.1. Flow chart of the donor blood from the donor selection until the donor blood is released
from Nlood Transfusin Service (BTS)/ Unit Transfusi Darah (UTD) to hospital blood bank (HBB)
2.2, What kind of blood components do we have in Hospital Blood Bank?
2.3, How do we find safe blood donors? What are the requirements of blood donors?
2.4. How are the donor blood separated, processed and stored ?
2.5. How many kind of blood components can be separated from the whole donor blood ?
2.6. What is the indications of each blood components?
2.7. What are leukodepleted blood components (packed red cells/PRC, platelet concentrates?
09.30- 2,8. How are those leukodepleted blood components produced?
09.45 Discussion

09.30- Session 3
10.00 “Blood Banking” – Safe donor blood - Part 2
3.1. What do we do with the collected donor blood to detect the transfusion transmitted
diseases (TTD)? What test is the sensitive and specific one if we compare among the available
tests (quick test ?, ELISA, Nucleic acid testing (NAT), RT-PCR ?
3.2. How do we test the collected donor blood to determine blood group types (ABO-Rhesus
typing) in BTS / UTD and in hospital blood bank? (slide test, tube test, gell test, magnetic test,
 molecular tests?
10.00- 3.3. How do we test the collected donor blood to have the matched donor blood components
10.15 for the recipients/ patients (crossmatching between donor blood and recipeient blood) ?
3.4. What is Coombs test? When and what for do we do Coombs test?
3.5. How are the blood components released from the BTS to hospital blood banks?
3.6. What is a cold chain system in tranfering blood components from BTS to hospital blood
bank and from hospital blood bank to patients?

10.15- Coffee break

10.30

10.30- Session 4
11.00 “ Blood transfusion practice in hospitals”
4.1. Flow chart of the blood transfusion practice since a doctor prescribes / orders donor blood
components for a patient, to patient blood specimen collection until donor blood components
are tranfused to a patient
4.2, How does a patient blood specimen is collected?
4.3. What does the hospital blood bank do if the blood bank receives a patient blood specimen
4.4. How are blood components transfused to patients ?
4.5. How do we prepare a patient pre transfusion, monitor during and after blood transfusion?
4.6. What are the acute and delayed bood arnsfusion complications whic can be developed
during and after blood trasfusion?
4.7. What shoud we do if the blood tarnsfusion complication occur?
4.8.

11.00-
 PEDIATRIC ONCOLOGY MASTER CLASS
2.1. Cancers in pediatric patients; How should we do to have early diagnosis?
2.2. Supportive therapy and oncology emergency in pediatric cacer patients: What should we
know and do?

07.30 Formatted: Centered, Line spacing: 1.5 lines

MEETING ROOM , level 8, FKUI ?? Formatted: Left, Line spacing: 1.5 lines
08.00 B, ROUND TABLE CROSS TALK (RTCT)-1 between Policy makers /Regulators, Producers & Clinicians on SAFE BLOOD DONORS and SAFE PLASMA DONORS
– (Collaboration program between the Indonesian Society of Hematology & Transfusion Medicine (ISHTM/PHTDI) and the Indonesian Society of Blood Bank Doctors/ PDTDI)

12.00
PRE – MEETING prior to the Round Table Cross Talk on Friday 24th 2017 in Shretaon Grand Hotel

08.00 PRE RTCT-1

1, SAFE BLOOD DONORS
1.2. How do we appropriately diagnose Transfusion transmitted infections (TTI)
08.15 of hepatitis B or C & HIV
by ELISA, NAT or RT-PCR methods/ techniques ?
1.3. If the blood donors are positive for TTI, what should we do with them? What is the role of VCT? Could the TTI positive donors donate again their bloods after the TTI is negative?

2.1. The role of vaccination in negative blood donors & anti-retrovirus (ARV) drugs in prositive blood donors of hepatitis B or C
2.2. The role of ARV drugs in blood donors with positif HIV
2.3. The safety of leucodepleted blood components compared to non filtered blood components
PANEL DISCUSSION
DRAFT of RECOMMENDATIONS from CLINICANS on “SAFE BLOOD DONORS for RECIPIENTS / PATIENTS” to MINISTRY of HEATLH, REPUBLIC INDONESIA